Alphamab Oncology (9966) Stock Statistics & Valuation Metrics

Alphamab Oncology has a market cap or net worth of HK$7.09B. The enterprise value is ―.

Alphamab Oncology has 965,141,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Alphamab Oncology’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 4.95%.

The current PE Ratio of Alphamab Oncology is 19.34. Alphamab Oncology’s PEG ratio is 0.23.

In the last 12 months, Alphamab Oncology had revenue of 640.08M and earned 166.34M in profits. Earnings per share was 0.17.

In the last 12 months, operating cash flow was -45.99M and capital expenditures -4.87M, giving a free cash flow of -50.86M billion.

Alphamab Oncology pays an annual dividend of ―, resulting in a dividend yield of ―

Alphamab Oncology upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.

Alphamab Oncology as a current ratio of 6.74, with Debt / Equity ratio of 10.15%

In the past 12 months, Alphamab Oncology has paid 0.00 in taxes.

Alphamab Oncology EV to EBITDA ratio is 14.61, with an EV/FCF ratio of 0.00.

Alphamab Oncology has HK$1.57B in cash and marketable securities with ¥185.96M in debt, giving a net cash position of -HK$1.39B billion.

Gross margin is 90.58%, with operating margin of 15.78%, and net profit margin of 25.99%.

The average price target for Alphamab Oncology is ―, which is 11.43% higher than the current price. The consensus rating is ―